Rectal Neuroendocrine Tumours

Česká verzia

Authors: O. Louthan
Authors place of work: IV. interní klinika 1. lékařské fakulty UK a VFN, Praha
Published in the journal: Klin Onkol 2009; 22(5): 195-201
Category: Přehledy

Summary

Rectal neuroendocrine tumours (carcinoids) belong to the hindgut carcinoid group, according to older classification. They are not associated with carcinoid syndrome. Colonoscopy is a gold standard for detecting rectal carcinoids. Endosonography is important for assessing rectal carcinoid growth. CT colonography and 111In-octreotide scanning is required for staging if residual or metastatic disease is suspected. Serum chromogranin A and acid phosphatase are necessary biochemical markers. Local resection is sufficient for small tumours, anterior resection for rectal tumours > 2cm is appropriate. There is no evidence base for adjuvant therapy. Patients with rectal carcinoids < 2cm have a very good prognosis with long term survival.

Key words:
carcinoid – rectal cancer – chromogranin A – OctreoScan – endosonography – therapy

Zdroje

1. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963; 281: 238–239.

2. Modlin IM, Kidd M, Latich I et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717–1751.

3. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13 715 carcinoid tumours. Cancer 2003; 97: 934–959.

4. Jetmore AB, Ray JE, Gathright JB et al. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992; 35: 717–725.

5. Capella C, Heitz PU, Hofler H et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995; 425: 547–560.

6. Onogawa S, Tanaka S, Oka S et al. Clinical significance of angiogenesis in rectal carcinoid tumors. Oncol Rep 2002; 9: 489–494.

7. Shimizu T, Tanaka S, Haruma K et al. Growth characteristics of rectal carcinoid tumors. Oncology 2000; 59: 229–237.

8. Hotta K, Shimoda T, Nakanishi Y et al. Usefulness Ki-67 for predicting the metastatic potential of rectal carcinoids. Pathol Int 2006; 56: 591–596.

9. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours. Springer-Verlag 2000.

10. Modlin IM, Öberg IK. A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Published by Felsenstein C.C.C.P.: 464.

11. Öberg K. Neuroendocrine gastrointestinal tumours. Annals of Oncology 1996; 7: 453–463.

12. Öberg K. Carcinoid Tumors: Current Concepts in Diagnosis and Treatment. The Oncologist 1998; 3: 339–345.

13. Matsumoto T, Iida M, Suekane H et al. Endoscopic ultrasonography in rectal carcinoid tumors: contribution to selection of therapy. Gastrointest Endosc 1991; 37: 539–542.

14. Banzo J, Vidal-Sicat S, Prats E et al. In-111 DTPA octreotide scintigraphy and intraoperative gamma probe detection in the diagnosis and treatment of residual lymph node metastases of a rectal carcinoid tumor. Clin Nucl Med 2005; 30: 308–311.

15. Matsushita M, Takakuwa H, Nishio A. Management of rectal carcinoid tumors. Gastrointest Endosc 2003; 58: 641.

16. Kinoshita T, Kanehira E, Omura K et al. Transanal endoscopic microsurgery in the treatment of rectal carcinoid tumor. Surg Endosc 2007; 21: 970–974.

17. Anděl P, Dostalík J, Pelikán A et al. Transanální endoskopická mikrochirurgie ve FN Ostrava. Čes a Slov Gastroent a Hepatol 2007; 61(5): 264–268.

18. Onozato Y, Kakizaki S, Ishihara H et al. Endoscopic submucosal dissection for rectal tumors. Endoscopy 2007; 39: 423–427.

19. Shirouzou K, Isomoto H, Kakegawa T et al. Treatment of rectal carcinoid tumors. Am J Surg 1990; 160: 262–265.

20. Schindl M, Niederle B, Hafner M et al. Stage-dependent therapy of rectal carcinoid tumors. World J Surg 1998; 22: 628–633.

21. Koura AN, Giacco GG, Curley SA et al. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997; 79: 1294–1298.

22. Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumours. Adv Surg 1995; 28: 317–336.

23. Ahlman H, Wängberg B, Jansson S et al. Interventional Treatment of Gastrointestinal Neuroendocrine Tumours. Digestion 2000; 62 (Suppl 1): 59–68.

24. Ramage JK, Goretzki PE, Manfredi R et al. Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well Differentiated Colon and Rectum Tumour/Carcinoma. Neuroendocrinology 2008; 87: 31–39.

25. O’Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 2003; 10: 463–468.

26. Öberg K. Established Clinical Use of Octreotide and Lanreotide in Oncology. Chemotherapy 2001; 47: 40–53.

27. Van Essen M, Krenning EP, De Jong M et al. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007; 46: 723–734.

28. Coldwell D, Kennedy AS, Van Echo DA. Comparative side effects of yttrium-90 based intra-arterial brachytherapy. J Clin Oncol 2004; 22: 3760.

29. Otte A, Mueller-Brand J, Dellas S et al. Yttrium-90-labelled somatostatin analogue for cancer treatment. The Lancet 1998; 351: 417–418.